 Other medical news, there's a new hope for Alzheimer's patients now that the FDA has approved a second drug to fight the most common cause of dementia. More from Allison Keys. E. Lilly's drug, Denanamab, targets the amyloid plaque buildup in the brain that can lead to the cell death and tissue loss found in Alzheimer's patients. It's very similar to the Japanese drug, Leukembi. A Lilly study found that patients getting the monthly treatment declined about 22% more slowly in terms of memory and cognitive abilities.